--- title: "Evidence: electron-transport cofactor" description: "Ubiquinol supplementation may improve endothelial function in patients with heart failure with reduced ejection fraction." url: "https://magellanlongevity.com/study/s121.md" canonical: "https://magellanlongevity.com/study/s121.html" html: "https://magellanlongevity.com/study/s121.html" type: "study" study_key: "s121" journal: "Am J Cardiovasc Drugs" year: 2020 pmid: "31713723" doi: "10.1007/s40256-019-00384-y" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # Evidence: electron-transport cofactor [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Evidence: electron-transport cofactor **HTML version:** https://magellanlongevity.com/study/s121.html · **In the Magellan app:** https://magellanlongevity.com/#/study/s121 ## Citation | Field | Value | | --- | --- | | Journal | Am J Cardiovasc Drugs | | Year | 2020 | | PMID | [31713723](https://pubmed.ncbi.nlm.nih.gov/31713723/) | | DOI | [10.1007/s40256-019-00384-y](https://doi.org/10.1007/s40256-019-00384-y) | | Study key | s121 | ## Takeaway Ubiquinol supplementation may improve endothelial function in patients with heart failure with reduced ejection fraction. ## The question Does ubiquinol improve peripheral endothelial function in patients with heart failure with reduced ejection fraction (HFrEF)? ## Hypothesis Ubiquinol improves peripheral endothelial function in patients with HFrEF. ## Methods This was a randomized, double-blind, placebo-controlled, crossover pilot study involving 14 patients with stable HFrEF. Patients received either ubiquinol 400 mg/day or placebo for 3 months, followed by a 1-month washout period and then crossover to the alternative treatment. Peripheral endothelial function was assessed using the reactive hyperemia index (RHI) and analyzed using the natural logarithm of RHI (LnRHI) before and after each treatment. ## Results Peripheral endothelial function, as assessed by LnRHI, tended to improve with ubiquinol 400 mg/day for 3 months (p = 0.076). Original RHI values significantly improved with ubiquinol treatment (pre-RHI 1.57, post-RHI 1.74, p = 0.026), but not with placebo (pre-RHI 1.67, post-RHI 1.51, p = 0.198). ## Conclusion Ubiquinol 400 mg/day for 3 months significantly improved peripheral endothelial function in patients with HFrEF. ## Limitations This was a pilot study with a small sample size (14 patients). ## Verbatim from the abstract > Ubiquinol led to significant improvement in peripheral endothelial function ## Change in Reactive Hyperemia Index (RHI) with Ubiquinol vs. Placebo | Measure | Reactive Hyperemia Index (RHI) | | --- | --- | | Ubiquinol Pre-treatment | 1.57 | | Ubiquinol Post-treatment | 1.74 | | Placebo Pre-treatment | 1.67 | | Placebo Post-treatment | 1.51 | *RHI values before and after 3 months of ubiquinol or placebo treatment.* ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | Ubiquinol (Reduced CoQ10) | Moderate evidence | [Ubiquinol (Reduced CoQ10)](https://magellanlongevity.com/p/121.md) | ## Reference 1. **Evidence: electron-transport cofactor** Am J Cardiovasc Drugs 2020 · [PMID 31713723](https://pubmed.ncbi.nlm.nih.gov/31713723/) · [DOI 10.1007/s40256-019-00384-y](https://doi.org/10.1007/s40256-019-00384-y) > Ubiquinol led to significant improvement in peripheral endothelial function ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/s121.html#page","url":"https://magellanlongevity.com/study/s121.html","name":"Evidence: electron-transport cofactor","description":"Ubiquinol supplementation may improve endothelial function in patients with heart failure with reduced ejection fraction.","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/s121.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Evidence: electron-transport cofactor","item":"https://magellanlongevity.com/study/s121.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/s121.html#study","name":"Evidence: electron-transport cofactor","headline":"Evidence: electron-transport cofactor","datePublished":"2020","isPartOf":{"@type":"Periodical","name":"Am J Cardiovasc Drugs"},"identifier":"PMID:31713723","url":"https://pubmed.ncbi.nlm.nih.gov/31713723/","sameAs":"https://doi.org/10.1007/s40256-019-00384-y","abstract":"Ubiquinol supplementation may improve endothelial function in patients with heart failure with reduced ejection fraction."}]} ``` ## Related on Magellan Longevity - [Ubiquinol (Reduced CoQ10)](https://magellanlongevity.com/p/121.md) — product graded on this and related evidence - [Ubiquinol in patients with severe sepsis or septic shock: a randomized, double-blind,…](https://magellanlongevity.com/study/d26130237.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).